Under construction – not a live service

Skip to content

Frontlight Research

Trial site

START | Midwest

Grand Rapids, Michigan, United StatesNot linked to an institution yet

66running trials
29closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Recruiting
JUR-003 in Adult Patients With Metastatic Prostate Cancer
NCT07824349· Phase 1· Source
Recruiting
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991· Phase 1· Source
Recruiting
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
NCT07809906· Phase 1· Source
Recruiting
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
NCT07746713· Phase 1· Source
Not yet recruiting
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
NCT07707674· Phase 1· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795· Phase 2· Source
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035· Phase 1· Source
Recruiting
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
NCT07652242· Phase 1· Source
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361· Phase 1· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559· Phase 2· Source
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676· Phase 1/2· Source
Recruiting
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT07454642· Phase 1· Source
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833· Phase 1· Source
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758· Phase 2· Source
Recruiting
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
NCT07280013· Phase 1· Source
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
NCT07321106· Phase 1· Source
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537· Phase 1· Source
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562· Phase 1· Source
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814· Phase 1· Source
Enrolling by invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003· Phase 1· Source
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171· Phase 1· Source
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313· Phase 1· Source
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583· Phase 1/2· Source
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255· Phase 1/2· Source
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257· Phase 1/2· Source
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204· Phase 1· Source
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
NCT07079631· Phase 1/2· Source
Recruiting
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
NCT06969430· Phase 1/2· Source
Recruiting
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
NCT06975293· Phase 1/2· Source
Recruiting
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347· Phase 2· Source
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521· Phase 1/2· Source
Recruiting
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
NCT06880549· Phase 1· Source
Recruiting
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128· Phase 1/2· Source
Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301· Phase 1· Source
Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987· Phase 1· Source
Recruiting
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185· Phase 1/2· Source
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193· Phase 1· Source
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319· Phase 1· Source
Recruiting
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT06433947· Phase 1· Source
Active, not recruiting
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987· Phase 1· Source
Active, not recruiting
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662· Phase 1· Source
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470· Phase 1· Source
Active, not recruiting
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837· Phase 1/2· Source
Recruiting
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NCT06234423· Phase 1· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245· Phase 1· Source
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157· Phase 1· Source
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840· Phase 1· Source
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551· Phase 1/2· Source
Recruiting
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988· Phase 1/2· Source
Active, not recruiting
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer24 recruiting
Colorectal cancer16 recruiting
Pancreatic cancer14 recruiting
Ovarian cancer11 recruiting
Prostate cancer9 recruiting
Gastric and esophageal cancer8 recruiting
Bladder cancer7 recruiting
Endometrial cancer7 recruiting
Cervical cancer5 recruiting
Head and neck cancer5 recruiting
Liver and biliary tract cancer4 recruiting
Sarcoma4 recruiting
Triple-negative breast cancer4 recruiting
Acute myeloid leukemia3 recruiting
Kidney cancer3 recruiting
Melanoma3 recruiting
Metastatic breast cancer3 recruiting
Multiple myeloma3 recruiting
Chronic lymphocytic leukaemia2 recruiting
Neuroendocrine tumours2 recruiting
Childhood cancers1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Follicular lymphoma1 recruiting
Glioblastoma1 recruiting
Mantle cell lymphoma1 recruiting
Mesothelioma1 recruiting
Myeloproliferative neoplasms1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Terminated
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
NCT06974734· Phase 1· Source
Terminated
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
NCT06580938· Phase 1· Source
Terminated
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
NCT06546553· Phase 1· Source
Terminated
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
NCT06364696· Phase 1· Source
Terminated
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
NCT06285097· Phase 1· Source
Terminated
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
NCT06270082· Phase 1· Source
Terminated
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
NCT05980416· Phase 1· Source
Terminated
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
NCT05827614· Phase 1· Source
Terminated
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
NCT05388435· Phase 1/2· Source
Completed
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
NCT05483933· Phase 1· Source
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595· Phase 1/2· Source
Terminated
A Study of SGN-ALPV in Advanced Solid Tumors
NCT05229900· Phase 1· Source
Terminated
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
NCT05242822· Phase 1· Source
Terminated
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
NCT05275439· Phase 1· Source
Completed
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT05259696· Phase 1/2· Source
Terminated
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
NCT05228015· Phase 1· Source
Completed
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
NCT05162755· Phase 1· Source
Completed
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
NCT04455841· Phase 1/2· Source
Terminated
PF-07284892 in Participants With Advanced Solid Tumors
NCT04800822· Phase 1· Source
Completed
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
NCT04672434· Phase 1· Source
Completed
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
NCT04641871· Phase 1· Source
Completed
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
NCT04570839· Phase 1/2· Source
Completed
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
NCT04344795· Phase 1· Source
Completed
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04354246· Phase 1· Source
Terminated
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT04278144· Phase 1/2· Source
Terminated
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
NCT04171141· Phase 1· Source
Terminated
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624· Phase 1· Source
Completed
MGD019 DART® Protein in Unresectable/Metastatic Cancer
NCT03761017· Phase 1· Source
Completed
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
NCT03667716· Phase 1· Source

Site data: ClinicalTrials.govUpdated 11 Nov 2026

Report an error